Alzheimer Disease - 17/10/18
Doi : 10.1016/j.cger.2018.06.006
John E. Morley, MB,BCh a, ⁎ 
, Susan A. Farr, PhD a, b, Andrew D. Nguyen, PhD a
, Susan A. Farr, PhD a, b, Andrew D. Nguyen, PhD a a Division of Geriatric Medicine, Saint Louis University School of Medicine, 1402 South Grand Boulevard, M238, St Louis, MO 63104, USA
b Research and Development Service, VA Medical Center, St Louis, MO, USA
∗Corresponding author. Division of Geriatric Medicine, Saint Louis University School of Medicine, 1402 South Grand Boulevard, M238, St Louis, MO 63104.Division of Geriatric MedicineSaint Louis University School of Medicine1402 South Grand BoulevardM238St LouisMO63104
Résumé |
Alzheimer disease is due to increased amyloid-β coupled with low progranulin. Several brain imaging techniques are helpful in the diagnosis. Drugs available for treating Alzheimer disease have limited clinical utility. Cognitive stimulation therapy is an effective therapy for persons with moderate Alzheimer disease.
Le texte complet de cet article est disponible en PDF.Keywords : Amyloid-β, Cognitive stimulation therapy, Progranulin, SAMP8, Biomarkers, Olive oil
Plan
| Disclosures: The authors have nothing to disclose. |
© 2018
Elsevier Inc. Tous droits réservés.
Vol 34 - N° 4
P. 591-601 - novembre 2018 Retour au numéro
Article précédent
- Mild Cognitive Impairment in Geriatrics
- Eric G. Tangalos, Ronald C. Petersen
- Lewy Body Dementia
- Angela M. Sanford
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?